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Angiotensin II receptor blocker inhibits p27Kip1 expression in
glucose-stimulated podocytes and in diabetic glomeruli.
Background. Diabetic nephropathy is characterized by
glomerular and tubular hypertrophy, and angiotensin II recep-
tor blockers (ARBs) are known to prevent renal hypertrophy
in diabetic patients.
Methods. To determine the effect of ARB on podocyte
p27Kip1 mRNA and protein expression, podocytes were ex-
posed to 5.6 mmol/L normal glucose or 25 mmol/L high glu-
cose with or without ARB, 10−7 mol/L L-158,809. For animal
studies, streptozotocin-induced diabetic rats were left untreated
or were treated with 1 mg/kg/day L-158,809 for 3 months (di-
abetes mellitus + ARB). Competitive reverse transcription-
polymerase chain reaction (RT-PCR), Western blot, immuno-
histochemistry, and morphometric analyses were performed.
Results. p27Kip1 mRNA and protein expression in podocytes
exposed to high glucose and in 3-month diabetic glomeruli were
significantly increased (P < 0.01). High glucose significantly in-
creased angiotensin II levels both in cell lysates and in media
compared with normal glucose (P < 0.05) and exogenous an-
giotensin II also increased p27Kip1 mRNA and protein expres-
sion in podocytes. L-158,809 treatment in podocytes inhibited
the increase in p27Kip1 mRNA expression by 84%, and protein
expression by 89% (P < 0.05). p27Kip1 mRNA and protein ex-
pression in diabetic + ARB glomeruli were also significantly
reduced by 78% and 85%, respectively, compared with diabetic
glomeruli (P < 0.01). ARB treatment also significantly ame-
liorated increased glomerular p27Kip1 expression in diabetes
mellitus as assessed by immunohistochemistry (P < 0.01). The
increase in glomerular volume in diabetes mellitus was also in-
hibited by 81% with ARB treatment (P < 0.05).
Conclusion. p27Kip1 mRNA and protein expression were
increased in diabetic glomeruli as well as in high glucose–
stimulated podocytes, and this increment in p27Kip1 expression
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was ameliorated by ARB treatment. These findings indicate
that ARB treatment has an additional effect on preventing re-
nal hypertrophy in diabetes mellitus.
The molecular and cellular mechanisms responsible
for diabetic nephropathy remain incompletely resolved.
While studies indicate the involvement of hyperglycemia
via the stimulation of growth factor-induced cellular
hypertrophy [1, 2], the increased production of extra-
cellular matrix (ECM) protein [3], and the decreased
production of matrix-degrading proteinases [4], the un-
derlying pathways mediating these processes have been
less well explored.
Kidney size is typically increased in diabetes, even at
the time of diagnosis [5]. This is primarily due to glomeru-
lar and tubular hypertrophy, although some low-grade
proliferation of glomerular cells is present in the early
phase [6, 7]. Cell culture experiments using mesangial
cells under high glucose conditions and in vivo studies in
various models of diabetes suggest a biphasic growth re-
sponse [6, 8, 9]. Initially, self-limited proliferation occurs,
followed by cell cycle arrest and hypertrophy, and the lat-
ter hypertrophic mechanism requires the combined effect
of mitogen-induced entry into the cell cycle and subse-
quent arrest at the G1/S interphase. Numerous studies
have demonstrated this cell cycle arrest is principally me-
diated by inhibitors of cyclin-dependent kinase (CDK),
namely CDK inhibitors (CKIs) [10–13], which are clas-
sified into two groups according to their structural ho-
mology: the INK family (p15, p16, p18, and p19) and the
Cip/Kip family (p21, p27, and p57).
Increased p27Kip1 protein expression was observed in
glomeruli from diabetic BBdp rats and db/db mice, mod-
els of type 1 and type 2 diabetes, respectively [13, 14].
Previous work has shown that high glucose also increases
p27Kip1 expression in cultured mesangial cells via a pro-
tein kinase C (PKC)-dependent pathway and also partly
by inducing transforming growth factor-b (TGF-b) [11].
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Since the intrarenal renin-angiotensin system (RAS) is
activated during diabetes [15], angiotensin II is consid-
ered as an important mediator of diabetic nephropathy
in addition to the effects of high glucose per se.
Normalizing blood glucose levels and inhibiting an-
giotensin II effects with angiotensin-converting en-
zyme (ACE) inhibitor or angiotensin II receptor
blocker (ARB) are now standard treatment for diabetic
nephropathy. Numerous studies have shown that ACE in-
hibitors and ARB prevent glomerular hypertrophy and
slow the progression of diabetic nephropathy in various
in vivo models of diabetes and in diabetic patients [14,
16–19]. In addition, Wolf et al [14] demonstrated that
the ACE inhibitor, enalapril, attenuated glomerular hy-
pertrophy in diabetic BBdp rats, which may contribute to
the reduced glomerular expression of p16INK4 and p27Kip1
protein. Furthermore, enalapril and losartan suppressed
the glomerular expression of the TGF-b receptor and
TGF-b1 protein, respectively, in rats with experimental
diabetes, suggesting a new mechanism of action of ACE
inhibitor and ARB in regulating the development of di-
abetic nephropathy [20, 21].
In this report, we examined the effect of ARB on
glomerular p27Kip1 mRNA and protein expressions in
streptozotocin-induced diabetic rats and in cultured
podocytes under high glucose conditions.
METHODS
Podocyte culture
Conditionally immortalized mouse podocytes were
kindly provided by Dr. Peter Mundel (Albert Einstein
College of Medicine, Bronx, NY) and were cultured
as previously described [22]. Briefly, frozen podocytes
were first grown under permissive conditions at 33◦C in
RPMI-1640 media containing 10% fetal bovine serum
(FBS), 50 U/mL interferon-c (INF-c) and 100 U/mL
of penicillin/streptomycin in collagen-coated flasks, and
the INF-c tapered down to 10 U/mL in successive pas-
sages. Cells were then trypsinized and subcultured with-
out INF-c (nonpermissive conditions) and allowed to
differentiate at 37◦C with media changed on alternate
days. Differentiation of podocytes grown for 10 days
at 37◦C was confirmed by the identification of synap-
topodin, a podocyte differentiation marker, by reverse
transcription-polymerase chain reaction (RT-PCR) and
Western blotting.
After confirming differentiation of podocytes and
serum restriction for 24 hours, medium was changed to
RPMI medium containing normal glucose (5.6 mmol/L
glucose), normal glucose + mannitol (19.4 mmol/L man-
nitol), normal glucose + angiotensin II (10−9 mol/L),
or high glucose (25 mmol/L glucose) with or without
10−7 mol/L L-158,809, a selective angiotensin II type 1
receptor blocker. After 3 days, cells were harvested for
either RNA or protein.
Assessment of cellular hypertrophy
Hypertrophy was assessed by measurement of cellular
protein/cell counts and by flow cytometry. After seed-
ing podocytes on 100 mm dishes and serum restriction
for 24 hours, medium was changed as above, and after
3 days the cells were harvested with 0.05% trypsin and
0.25 mmol/L ethylenediaminetetraacetic acid (EDTA),
pelleted at 1500g for 5 minutes, and resuspended in
phosphate-buffered saline (PBS). Aliquots of podocytes
were used for cell counts using a hemocytometer, and
remaining cells were lysed in 0.5 mol/L NaOH and total
protein content was measured by using a modified Lowry
method. To determine the cell size directly, cells were
harvested by trypsinization after 3 days of treatment as
above, fixed with 75% methanol, washed, and incubated
with 100 lg/mL RNase and 10lg/mL propidium iodide
in PBS for 1 hour at 37◦C. Samples were analyzed then
analyzed by forward light scattering on a FACScan flow
cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Data were computer analyzed with Cell Quest Pro soft-
ware (BD Biosciences).
Measurement of angiotensin II levels
Angiotensin II levels were determined in podocyte ex-
tracts and in media. After seeding podocytes on 100 mm
dishes and serum restriction for 24 hours, medium was
changed as above, and after 3 days the media were col-
lected and the cells were washed with ice-cold PBS,
scraped in extraction buffer [20 mmol/L Tris-HCl, pH 7.4,
10 mmol/L EDTA, 5 mmol/L ethyleneglycoltetraacetic
acid (EGTA), 5 mmol/L b-mercaptoethanol, 50 lg/mL
phenylmethyl sulfonyl fluoride (PMSF), 10 mmol/L ben-
zamidine, and 0.1lg/mL aprotinin], and homogenized.
Cell lysates and media were centrifuged at 12,000g for
10 minutes at 4◦C, and supernatants were collected.
Angiotensin II levels in the supernatants were deter-
mined using commercial enzyme-linked immunosorbent
assay (ELISA) kit (Peninsula Laboratories, Belmont,
CA, USA) as according to the manufacturer’s instruc-
tions and total protein content by using a modified Lowry
method.
Animals
All animal studies were conducted using approved pro-
tocols. Twenty-four male Sprague-Dawley rats, weighing
220 to 250 g were studied. Eight were injected with diluent
(control) and 16 with 65 mg/kg streptozotocin intraperi-
toneally. Blood glucose levels were measured 3 days after
the streptozotocin injection to confirm the development
of diabetes. Diabetic rats were then randomly assigned to
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two groups. One group, comprised of eight diabetic rats,
was treated with 1 mg/kg/day of L-158,809 by gavage (di-
abetes mellitus + ARB) for 3 months, and the remaining
eight diabetic rats were left untreated. The rats were given
free access to water and standard laboratory chow during
the 3-month study period. All rats were sacrificed after
3 months.
Body weights were checked monthly, and kidney
weights were measured at the time of sacrifice. Systolic
blood pressure was measured by tail-cuff phlethysmog-
raphy at 3 months. Serum glucose and 24-hour urinary
albumin were measured monthly. Blood glucose was
measured by glucometer and 24-hour urinary albumin
excretion was determined by ELISA (Nephrat II) (Exo-
cell, Inc., Philadelphia, PA, USA).
Total RNA extraction
Glomeruli were isolated by sieving. Purity of the
glomerular preparation was greater than 98% as deter-
mined by light microscopy. Total RNA was extracted as
previously described [23]. Briefly, addition of 100 lL of
RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX,
USA) to the glomeruli was followed by glomerular lysis
by freezing and thawing three times. Another 700 lL of
RNA STAT-60 reagent was added, the mixture vortexed,
and stored for 5 minutes at room temperature, 160 lL of
chloroform added, and the mixture shaken vigorously for
30 seconds. After 3 minutes, the mixture was centrifuged
at 12,000 g for 15 minutes at 4◦C and the upper aqueous
phase containing the extracted RNA was transferred to a
new tube. RNA was precipitated from the aqueous phase
by 400 lL isopropanol and pelleted with centrifugation at
12,000 g for 30 minutes at 4◦C. The RNA precipitate was
washed with 70% ice-cold ethanol, dried using Speed Vac,
and dissolved in diethyl pyrocarbonate (DEPC)-treated
distilled water. Total RNA from podocytes was extracted
similarly. Glomerular and podocyte RNA yield and qual-
ity were assessed based on spectrophotometric measures
at 260 and 280 wavelength.
RT
First-strand cDNA was made by using a Boehringer
Mannheim cDNA synthesis kit (Boehringer Mannheim
GmbH, Mannheim, Germany). Two micrograms of to-
tal RNA extracted from sieved glomeruli was reverse
transcribed using 10 lmol/L random hexanucleotide
primer, 1 mmol/L deoxynucleoside triphosphate (dNTP),
8 mmol/L MgCl2, 30 mmol/L KCl, 50 mmol/L Tris-HCl,
pH 8.5, 0.2 mmol/L dithiothreithol (DTT), 25 U RNAse
inhibitor, and 40 U avian myeloblastoma virus (AMV)
reverse transcriptase. The mixture was incubated at 30◦C
for 10 minutes and 42◦C for 1 hour, followed by inactiva-
tion of enzyme at 99◦C for 5 minutes. Cellular RNA from
each plate was similarly reverse transcribed.
PCR
The primers used for glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and p27Kip1 amplification were
as follows: GAPDH sense 5′-CCTGCACCACCAACT
GCTTAGC-3′ and antisense 5′-CCAGTGAGCTTCCC
GTTCAGC-3′; and p27Kip1 sense 5′-CGTGAGAGTGT
CTAACGGG-3′ and antisense 5′-CGAGTCAGGCAT
TTGGTCC-3′. cDNAs from 10 ng RNA of glomeruli and
podocytes per reaction tube were used for GAPDH and
20 ng RNA for p27Kip1.
For GAPDH and p27Kip1 mRNA expression, we used
quantitative competitive PCR. The competitor cDNA
was used as internal standard, and was designed to con-
tain the same base pair sequence as the target cDNA
that would allow efficient priming, but had a portion
deleted so that the competitor PCR-generated fragment
could be easily distinguished electrophoretically by size.
The RT-PCR products were separated by electrophore-
sis, the band densities analyzed by TINA image soft-
ware (Raytest, Straubenhardt, Germany), the values log
transformed, and a log-linear regression analysis was per-
formed against the competitor concentration for each
PCR tube. The quantity of cDNA in the test sample
was defined as the amount at which the competitor and
wild-type optical density bands were equal. PCR was per-
formed using cDNA, 1.25 U Taq polymerase, 20 lmol/L
dNTP, and 25 pmol sense and antisense primers in a
volume of 50 lL containing 1 × PCR buffer. The PCR
conditions used were as follows: for GAPDH, 38 cycles,
denaturation at 94◦C for 45 seconds, annealing at 60◦C
for 45 seconds, and extension at 72◦C for 1 minute; and
for p27Kip1, 40 cycles, denaturation at 94◦C for 45 seconds,
annealing at 60◦C for 45 seconds, and extension at 72◦C
for 1 minute. Initial heating at 95◦C for 3 minutes and
final extension at 72◦C for 7 minutes were performed for
all PCRs.
Western blot analysis
Sieved glomeruli and podocytes harvested from plates
were lysed in sodium dodecyl sulfate (SDS) sample buffer
[2% SDS, 10 mmol/L Tris-HCl, pH 6.8, and 10% (vol/vol)
glycerol]. Aliquots of 50 lg protein were treated with
Laemmli sample buffer, heated at 100◦C for 5 minutes,
and electrophoresed at 50 lg/lane in a 12% acrylamide
denaturing SDS-polyacrylamide gel. Proteins were then
transferred to a Hybond-enhanced chemiluminescence
(ECL) membrane using a Hoeffer semidry blotting ap-
paratus (Hoeffer Instruments, San Francisco, CA, USA),
the membrane was incubated in blocking buffer A (1 ×
PBS, 0.1% Tween-20, and 8% nonfat milk) for 1 hour
at room temperature, and incubated overnight at 4◦C
in a 1:1000 dilution of polyclonal antibody to p27Kip1
and b-actin (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). The membrane was then washed once for
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Fig. 1. A representative p27Kip1 competitive
reverse transcription-polymerase chain reac-
tion (RT-PCR) electrophoresis of podocytes
exposed to 5.6 mmol/L glucose (NG), 25
mmol/L glucose (HG), and HG + angiotensin
II receptor blocker (ARB) (10−7 mol/L
L-158,809). Each lane represents a competi-
tive RT-PCR reaction (40 cycles) with a fixed
amount of p27Kip1 wild-type cDNA (403 bp)
from the equivalent of 20 ng RNA and a
variable amount of p27Kip1 competitor cDNA
(298 bp) as follows: lane 1, 500 attmol/lL; lane
2, 100 attmol/lL; lane 3, 50 attmol/lL; lane 4,
10 attmol/lL; and lane 5, 5 attmol/lL.
15 minutes and twice for 5 minutes in 1 ×PBS with 0.1%
Tween-20, and incubated in buffer A with horseradish
peroxidase-linked goat antirabbit IgG (Amersham Life
Science, Inc., Arlington Heights, IL, USA) at 1:1000 di-
lution. The washes were repeated, and the membrane
developed with chemiluminescent agent (ECL) (Amer-
sham Life Science, Inc.).
Pathology
Coronal slices of kidney for routine light microscopy
were placed into alcoholic Bouin’s solution, processed in
the standard fashion, and sections were stained with pe-
riodic acid-Schiff (PAS). Slices of kidney for immunohis-
tochemical staining were fixed in 10% neutral buffered
formalin, processed in the standard manner, and 5 lm
sections were utilized. Slides were deparaffinized, hy-
drated in ethyl alcohol, and washed in tap water. Anti-
gen retrieval was carried out in 10 mmol/L sodium cit-
rate buffer for 20 minutes using a vegetable steamer. For
p27Kip1 staining, a polyclonal rabbit antimouse p27Kip1
antibody was diluted in 1:300 with 2% casein in bovine
serum albumin (BSA) and was applied for overnight
incubation at room temperature. After washing, a sec-
ondary goat antirabbit antibody was added for 20 min-
utes, the slides were washed and incubated with a ter-
tiary rabbit peroxidase-conjugated antiperoxidase (PAP)
complex for 20 minutes. Diaminobenzidine (DAB) was
added for 2 minutes and the slides were counterstained
with hematoxylin. Fifty glomeruli in each section were ex-
amined using light microscopy at a magnification of ×400,
and all nuclei stained positive for p27Kip1 per glomerulus
were counted for assessing p27Kip1 immunohistochemical
staining.
Morphometric measurement of glomerular volume
Glomerular volume (VG) was calculated according to
the method of Weibel [24]. Briefly, the surface areas of
20 glomeruli cut at the vascular pole on PAS-stained tis-
sue sections were traced along the outline of the capil-
lary loops using a computer-assisted color image analyzer
Image-Pro version 2.0 (Media Cybernetics, Silver Spring,
MD, USA). VG was calculated using the equation:
VG = b/k × (area)3/2
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Fig. 2. The p27Kip1/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA ratio of podocytes. The p27Kip1/GAPDH mRNA
ratio of podocytes exposed to high glucose (HG) was significantly
higher than that of podocytes in normal glucose (NG) media, and
10−7 mol/L L-158,809 treatment significantly inhibited the increase
in p27Kip1 mRNA expression by high glucose (N = 6 in each group).
Angiotensin II (AII) at a concentration of 10−9 mol/L significantly
increased p27Kip1 mRNA, whereas mannitol (M) (19.4 mmol/L) had
no effect on the p27Kip1 mRNA expression of podocytes. ∗P < 0.05
vs. normal glucose, normal glucose + mannitol, and normal glucose +
angiotensin II receptor blocker (ARB); #P < 0.05 vs. normal glucose
+ angiotensin II and high glucose.
where b = 1.38 is the shape coefficient for spheres, and
k = 1.1 is the size distribution coefficient.
Statistical analysis
All values are expressed as the mean ± standard error
of the mean (SEM). Statistical analysis was performed us-
ing the statistical package SPSS for Windows version 11.0
(SPSS, Inc., Chicago, IL, USA). Results were analyzed us-
ing Kruskal-Wallis nonparametric test for multiple com-
parisons. Significant differences by Kruskal-Wallis test
were further confirmed by Mann-Whitney U test. Sta-
tistical significance was determined when P values were
less than 0.05.
RESULTS
Cell culture studies
Podocytes p27Kip1 mRNA and protein expression. The
p27Kip1 mRNA of podocytes exposed to high glucose
(1.22 ± 0.17 attmol/ng RNA) was significantly higher
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Fig. 3. Western blot of p27Kip1 in podocytes (representative of six
blots). The p27Kip1 protein expression was significantly higher in high
glucose (HG) than normal glucose (NG) podocytes. There was a 1.7-
fold increase in p27Kip1 protein expression in high glucose compared
with normal glucose cells assessed by densitometry, and angiotensin
II receptor blocker (ARB) ameliorated this high glucose–induced in-
crease in p27Kip1 protein expression by 89%. AII at a concentration of
10−9 mol/L also significantly increased p27Kip1 protein, whereas manni-
tol (M) (19.4 mmol/L) had no effect on the p27Kip1 protein expression
of podocytes.
than that of podocytes in normal glucose media (0.58 ±
0.05 attmol/ng RNA) (P < 0.01), and 10−7 mol/L L-
158,809 treatment significantly inhibited the increase
in p27Kip1 mRNA expression by high glucose (0.68 ±
0.10 attmol/ng RNA) (P < 0.05) (Fig. 1). In contrast,
there was no significant difference in the amount of
GAPDH mRNA (data not shown). After correction for
GAPDH mRNA, the differences in p27Kip1 mRNA ex-
pression among the three groups remained significant
(p27Kip1/GAPDH mRNA: low glucose 5.3 ± 0.8 vs. high
glucose; 10.7 ± 0.9 vs. high glucose + ARB; 6.0 ± 1.0 (P <
0.05) (Fig. 2).
The p27Kip1 protein expression was also significantly
higher in high glucose than in normal glucose podocytes.
There was a 1.7-fold increase in p27Kip1 protein expres-
sion in high glucose compared with normal glucose cells
assessed by densitometry (P < 0.01), and ARB amelio-
rated this high glucose–induced increase in p27Kip1 pro-
tein expression (Fig. 3).
Angiotensin II at a concentration of 10−9 mol/L signif-
icantly increased p27Kip1 mRNA and protein expression,
whereas mannitol had no effect on the p27Kip1 mRNA
and protein expression of podocytes (Figs. 2 and 3).
Cellular hypertrophy. Cellular protein content was
significantly higher in podocytes under high glucose
medium than in cells under normal glucose medium with
no significant change in cell numbers, suggesting cellu-
lar hypertrophy. A 1.6-fold increase in the ratio of pro-
tein/cell numbers was observed in podocytes exposed to
high glucose, and the increment in the ratio of protein/cell
numbers by high glucose was significantly inhibited with
10−7 mol/L L-158,809 by 85% in podocytes (P < 0.05)
(Fig. 4A). Cellular hypertrophy was also confirmed by
FACScan flow cytometer (Fig. 4B). The relative cell size,
determined by mean forward light scattering, was 22%
larger in high glucose podocytes compared with that in
normal glucose podocytes, and 10−7 mol/L L-158,809 in-
hibited the increase in cell size of high glucose podocytes
by 89% (P < 0.05).
AII levels. High glucose significantly increased an-
giotensin II levels both in cell lysates and in media. An-
giotensin II levels in high glucose cell lysates (0.33 ±
0.03 pg/lg protein) and in high glucose media (4.91 ±
0.42 pg/lg protein) were 43% and 68% higher compared
with those in normal glucose cell lysates (0.23 ± 0.03 pg/lg
protein) and in normal glucose media (2.93 ± 0.53 pg/lg
protein), respectively (P < 0.05). Mannitol had no effect
on angiotensin II levels (Fig. 5).
Animal studies
Animal data. All animals gained weight over the 3-
month experimental period, but weight gain was highest
in control rats (P < 0.01) (Table 1). The ratio of kidney
weight to body weight in diabetic rats (1.64 ± 0.11%)
was significantly higher than in control (0.56 ± 0.05%)
and in diabetes mellitus + ARB rats (0.91 ± 0.04%) (P <
0.01). Treatment with ARB at the dose administered in
this study resulted in no significant reduction in systolic
blood pressure.
The mean blood glucose levels of control, diabetes mel-
litus, and diabetes mellitus + ARB rats were 112.1 ±
8.1 mg/dL, 495.5 ± 11.2 mg/dL, and 486.0 ± 12.1 mg/dL,
respectively (P < 0.01). Compared to the control (0.40 ±
0.06 mg/day), 24-hour urinary albumin excretion was sig-
nificantly higher in the diabetes mellitus group (1.99 ±
0.22 mg/day) (P < 0.05), and ARB treatment partly re-
versed the increase in albuminuria in diabetic rats (0.87 ±
0.13 mg/day) (P < 0.05).
Glomerular p27Kip1 mRNA and protein expression.
For the animal studies, we first examined the change
of glomerular p27Kip1 mRNA expression in control,
diabetes mellitus, and diabetes mellitus + ARB rats.
Glomerular p27Kip1 mRNA expression was significantly
higher in diabetes mellitus (1.44 ± 0.17 × 10−1 attmol/ng
RNA) than in control rats (0.53 ± 0.07 × 10−1 attmol/ng
RNA) at 3 months after diabetes mellitus induction (P <
0.01). ARB treatment for 3 months in diabetic rats nearly
normalized increased p27Kip1 mRNA expression (P <
0.01). In contrast, glomerular GAPDH mRNA expres-
sion in diabetes mellitus (1.16 ± 0.17 attmol/ng RNA)
was similar to those of the control (0.91 ± 0.06 attmol/ng
RNA) and diabetes mellitus + ARB groups (1.06 ±
0.11 attmol/ng RNA). Glomerular p27Kip1 mRNA re-
mained significantly higher in diabetes mellitus com-
pared to control rats, and ARB treatment ameliorated
the increase in p27Kip1 mRNA even after correcting
for GAPDH mRNA (p27Kip1/GAPDH mRNA: control
0.61 ± 0.07 × 10−1 vs. diabetes mellitus; 1.16 ± 0.10 ×
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Fig. 4. Cellular hypertrophy. (A) Protein/cell
numbers of podocytes. A 1.6-fold increase in
the ratio of protein/cell numbers was observed
in podocytes exposed to high glucose (HG),
and the increment in the ratio of protein/cell
numbers by high glucose was significantly in-
hibited with 10−7 mol/L L-158,809 by 85% in
podocytes (N = 6 in each group). ∗P < 0.05 vs.
normal glucose (NG), normal glucose + man-
nitol (M), and normal glucose + angiotensin
II receptor blocker (ARB). #P < 0.05 vs. high
glucose. (B) A representative FACScan of
podocytes exposed to normal glucose, high
glucose, and high glucose + ARB. The rel-
ative cell size, determined by mean forward
light scattering, was 22% larger in high glu-
cose podocytes compared with that in normal
glucose podocytes, and 10−7 mol/L L-158,809
inhibited the increase in cell size of high glu-
cose podocytes by 89% (P < 0.05).
10−1 vs. diabetes mellitus + ARB; 0.74 ± 0.14 × 10−1)
(P < 0.05) (Fig. 6).
Figure 7 shows a representative Western blot of equal
amounts of protein from the lysates of sieved control, di-
abetes mellitus, and diabetes mellitus + ARB glomeruli
at 3 months after streptozotocin injection. Glomerular
p27Kip1 protein expression was also increased in diabetic
rats, as shown by p27Kip1 mRNA expression, and admin-
istration of ARB in diabetic rats inhibited the increase
in glomerular p27Kip1 protein expression. Densitometric
quantitation revealed 2.8-fold increase in p27Kip1 protein
expression in diabetic vs. control rats, and ARB blocked
the increase by 85% (P < 0.01).
Pathology. The main positive-stained cells for p27Kip1
appeared to be visceral epithelial cells. The positive-
stained nuclei were significantly more in diabetes mellitus
(57.1 ± 7.3%) than in control glomeruli (21.3 ± 1.4%),
and they were significantly reduced by ARB treatment
(30.5 ± 4.3%) (P < 0.01) (Fig. 8).
Glomerular volume. The mean glomerular volume in
diabetes mellitus (1.48 ± 0.15 × 106 lm3) was 54.2%
larger than in control rats (0.96 ± 0.11 × 106 lm3) at
3 months after diabetes mellitus induction, and ARB
treatment for 3 months significantly prevented glomeru-
lar hypertrophy in diabetic rats (1.06 ± 0.06 × 106 lm3)
(P < 0.05).
DISCUSSION
In this study, we show that diabetic conditions, both in
vivo and in vitro, stimulate p27Kip1 mRNA and protein
expression of glomeruli and podocytes with concomitant
hypertrophy. This study also shows that angiotensin II,
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Fig. 5. Angiotensin II (Ang II) levels in cell lysates and in media. AII
levels in high glucose (HG) cell lysates and in high glucose media were
43% and 68% higher compared with those in normal glucose (NG)
cell lysates and in normal glucose media, respectively (N = 6 in each
group). Mannitol (M) had no effect on angiotensin II levels. ∗P < 0.05
vs. normal glucose and normal glucose + mannitol.
which is activated in the diabetic state, increased p27Kip1
mRNA and protein expression in podocytes. Finally, this
study demonstrates for the first time that glomerular hy-
pertrophy in diabetes mellitus and high glucose–induced
hypertrophy of podocytes were prevented by ARB treat-
ment, which might be attributed to the inhibition of
p27Kip1 mRNA and protein expression.
Diabetic nephropathy is characterized by glomerular
and tubular hypertrophy and increased ECM accumu-
lation [25]. The diabetic milieu per se, hemodynamic
changes, and local growth factors such as TGF-b and
angiotensin II are considered mediators in the patho-
genesis of cellular hypertrophy in diabetes [15, 26]. Re-
cent studies support the role of CKIs regulated by these
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Table 1. Body weight, kidney weight, systolic blood pressure, and
urinary albumin excretion of the rats
Diabetes mellitus +
Diabetes angiotensin II
Parameters Control mellitus receptor blocker
Body weight g 510.3 ± 24.2 266.3 ± 18.5a 284.5 ± 21.5a
Kidney weight/body
weight %
0.56 ± 0.05 1.64 ± 0.11a 0.91 ± 0.04b
Systolic blood
pressure mm Hg
116.5 ± 4.9 121.3 ± 8.2 119.5 ± 6.7
Blood glucose
mg/dL
112.1 ± 8.1 495.5 ± 11.2a 486.0 ± 12.1a
Urinary albumin
excretion mg/day
0.40 ± 0.06 1.99 ± 0.22c 0.87 ± 0.13d
aP < 0.01 vs. control; bP < 0.01 vs. diabetes mellitus; cP < 0.05 vs. control;
dP < 0.05 vs. diabetes mellitus.
mediators in the development of diabetic nephropathy
[9, 27–29]. High glucose, in the absence of other exoge-
nous growth factors, was found to induce p27Kip1 pro-
tein expression in cultured rat mesangial cells [11] and
treatment with p27Kip1 antisense oligonucleotides pre-
vented this glucose-induced hypertrophy, resulting in a
proliferative phenotype [11]. In recent study, p27Kip1 pro-
tein expression was also found to be increased in cul-
tured podocytes exposed to high glucose [31]. In addition,
glomerular p27Kip1 or p21Cip1 protein expression were in-
creased in diabetic db/db mice, a model of type 2 dia-
betes [13], and in streptozotocin-induced type 1 diabetes
[12, 14]. In this study, we demonstrated that p27Kip1 pro-
tein expression was increased, as assessed by Western
blot in diabetic glomeruli and in podocytes under high
glucose conditions, in accordance with previous studies
[11, 13, 14, 31]. The immunohistochemical staining also
revealed that glomerular p27Kip1 protein expression was
increased in diabetic rats, which was in accord with the
results of the Western blot. In addition, p27Kip1 mRNA
expression was increased in diabetic glomeruli and in high
glucose–stimulated podocytes along with p27Kip1 protein,
which differs from the results of Wolf et al [11, 13]. Al-
though the reasons for this divergence in mRNA levels
are unclear, species differences and differences in dia-
betes duration or in the degree of hyperglycemia may
contribute. A recent observation that p27Kip1 mRNA ex-
pression was increased, with a concomitant increase in
p27Kip1 protein expression by mechanical stress in differ-
entiated podocytes cultured under nonpermissive condi-
tions [32], supports our results. Taken together, it seems
that glomerular hypertrophy in diabetes is a consequence
of the hypertrophy of podocytes as well as mesangial cells.
In this study, we also demonstrate for the first time that
angiotensin II increased p27Kip1 mRNA and protein ex-
pression in podocytes. Angiotensin II is considered a me-
diator in the pathogenesis of diabetic nephropathy and
atherosclerosis [15, 33]. It exerts a hypertrophic effect on
renal tubular cells [27, 34], mesangial cells [11], and vas-
cular smooth muscle cells (VSMCs) [33]. In podocytes,
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Fig. 6. The p27Kip1/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA ratio in control, diabetes mellitus (DM), and DM
+angiotensin II receptor blocker (ARB) glomeruli at 3-month after
streptozotocin injection. Glomerular p27Kip1/GAPDH mRNA ratio
was significantly higher in diabetes mellitus than in control rats at 3
months after diabetes mellitus induction, and ARB treatment for 3
months in diabetic rats nearly normalized increased p27Kip1/GAPDH
mRNA ratio (N = 8 in each group). ∗P < 0.05 vs. control; #P < 0.05 vs.
diabetes mellitus.
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Fig. 7. Western blot of p27Kip1 in control, diabetes mellitus (DM), and
DM + angiotensin II receptor blocker (ARB) glomeruli at 3 months
after streptozotocin injection (representative of five blots). Glomerular
p27Kip1 protein expression was increased in diabetic rats, and admin-
istration of ARB in diabetic rats inhibited the increase in glomerular
p27Kip1 protein expression. Densitometric quantitation revealed 2.8-
fold increase in p27Kip1 protein expression in diabetic vs. control rats,
and ARB blocked the increase by 85%.
angiotensin II is known to mediate rearrangement of
the actin cytoskeleton [35], depolarization and increase
in cytosolic calcium activity [36], and apoptosis [37]. In
addition, the intraperitoneal infusion of angiotensin II
reduced tubular proliferation as detected by proliferating
cell nuclear antigen (PCNA) in Wistar rats, and resulted
in tubular hypertrophy [27]. To understand the under-
lying molecular mechanism of angiotensin II–induced
hypertrophy, a number of investigations have been per-
formed upon the effect of angiotensin II on cell cycle
regulatory proteins and CKIs. Angiotensin II induced
p27Kip1 protein expression, but not mRNA expression, in
renal tubular cells in vivo and in vitro [27, 38]. TGF-b ,
which has been implicated in diabetes-induced renal
growth and in the transformation of a mitogenic stimulus
to hypertrophy [26, 29], is also induced by angiotensin
II in mesangial cells [38] and VSMCs [39]. Moreover,
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Fig. 8. Immunohistochemical staining for
p27Kip1 protein in control, diabetes mellitus
(DM), and DM + angiotensin II receptor
blocker (ARB) glomeruli at 3 months after
streptozotocin injection. The main positive-
stained cells for p27Kip1 appeared to be vis-
ceral epithelial cells. There was a significant
increase in glomerular p27Kip1 expression in
diabetic vs. control rats, and ARB treatment
in diabetes mellitus for 3 months significantly
inhibited the increment in p27Kip1 protein ex-
pression (×400).
exogenous TGF-b treatment not only increased p27Kip1
protein expression [40] but also led to a down-regulation
of cyclin D and the induction of p16INK4 with the potential
liberation of p27Kip1, which could bind to cyclin E and fur-
ther reinforce G1 phase arrest and cellular hypertrophy
[41, 42].
ACE inhibitors or ARB treatment, which became the
standard therapy for diabetic nephropathy, may prevent
or even reverse renal hypertrophy in diabetes [16–19].
In addition, loss of podocytes and podocyte hypertro-
phy, which are important pathologic findings of diabetic
nephropathy, were also prevented by ACE inhibition
[19]. Although the restoration to normal of glomerular
hyperfiltration could account for this effect, blocking the
hypertrophic effect of TGF-b induced by angiotensin II
and/or the increase in CKIs induced by TGF-b and an-
giotensin II may also contribute. Wolf et al [14] observed
that the glomerular expression of p16INK4, p21Cip1, and
p27Kip1 were all stimulated in diabetic BBdp rats, and
that enalapril treatment for 3 weeks reduced the pro-
tein expression of p16INK4 and p27Kip1, but not of p21Cip1.
Intracellular reactive oxygen species, produced by an-
giotensin II–induced membrane nicotinamide adenine
dinucleotide phosphate (NADPH) activity, may also play
an important role in p27Kip1 expression [28]. Increased
oxidative stress is characteristic of diabetic conditions
and could further stimulate p27Kip1 expression [28]. Since
enalapril is known to have direct antioxidant effects [43]
and to inhibit the hydrogen peroxide formation induced
by high glucose in cultured mesangial cells [44], it has
been suggested that the effect of enalapril on p27Kip1 ex-
pression could be related to an inhibition of oxygen rad-
ical formation. However, one study demonstrated that
enalapril treatment for 32 weeks in OLEFT rats had no
effect on lipid peroxide content in the renal cortex or on
the activity of either superoxide dismutase or glutathione
peroxidase [45]. In this study, we demonstrate that ARB
also inhibits increased glomerular p27Kip1 expression in
diabetic rats. Taken together, the observation that either
ACE inhibitor or ARB inhibits p27Kip1 expression sug-
gests that the mechanism is related to an angiotensin II
blockade rather than direct antioxidant effects. To under-
stand the mechanism by which ARB inhibited increased
p27Kip1 expression in high glucose–stimulated podocytes,
we measured angiotensin II levels in cell lysates as well
as in media. Based on the fact that podocytes express
angiotensin II type 1 receptor [46] and the results that
angiotensin II levels were increased by high glucose and
exogenous angiotensin II increased p27Kip1 expression in
podocytes, we suggest that L-158,809 inhibited p27Kip1 ex-
pression in podocytes under high glucose conditions by
blocking the effect of increased angiotensin II. Recent ev-
idence has also shown that angiotensin II production was
increased in podocytes, even though the stimulus was me-
chanical strain, and the increase in angiotensin II induced
apoptosis, mainly in an angiotensin II type 1 receptor-
mediated fashion [37].
Morphometric studies have shown that nephromegaly
in diabetes is due to an increase in glomerular and tubu-
lar cell size and that this is associated with glomerular hy-
pertrophy [25]. Hajinazarian et al [47] demonstrated that
the ACE inhibitor, captopril, prevented the development
of renal cell hypertrophy, glomerular hypertrophy, and
mesangial matrix expansion, as assessed by morphome-
try. In this study, we also demonstrate that the inhibitory
effect of ARB on p27Kip1 mRNA and protein expres-
sion results in the attenuation of podocyte and glomerular
hypertrophy.
CONCLUSION
p27Kip1 mRNA and protein expression were increased
in podocytes exposed to high glucose media and in
streptozotocin-induced diabetic glomeruli, and this incre-
ment in p27Kip1 expression was abrogated by ARB treat-
ment. Besides lowering the systemic and intraglomerular
pressure, these findings suggest an additional advantage
of ARB in the management of diabetic nephropathy.
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